Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA

Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA

Naomi V Dahl,1 Robert F Kaper,2 William E Strauss,1 Frank A Corvino,3 Marko Zivkovic3 1Medical Affairs, 2Medical & Scientific Affairs, AMAG Pharmaceuticals, Inc., Waltham, MA, 3Genesis Research, Hoboken, NJ, USA Objective: Ferumoxytol has demonstrated superior efficacy compared with oral iro...

Full description

Bibliographic Details
Main Authors: Dahl NV, Kaper RF, Strauss WE, Corvino FA, Zivkovic M
Format: Article
Language:English
Published: Dove Medical Press 2017-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
incremental cost-effectiveness ratio (ICER)
health care costs
intravenous iron
iron therapy
erythropoietin
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-intravenous-ferumoxytol-for-the-treatme-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-intravenous-ferumoxytol-for-the-treatme-peer-reviewed-article-CEOR

Similar Items